These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2). Maveddat A; Mallah H; Rao S; Ali K; Sherali S; Nugent K Int J Occup Environ Med; 2020 Oct; 11(4):157-178. PubMed ID: 33098401 [TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic or relapsing COVID-19 in immunodeficiency. Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850 [TBL] [Abstract][Full Text] [Related]
4. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
9. Treatment of COVID-19: a review of current and prospective pharmacotherapies. Quek E; Tahir H; Kumar P; Hastings R; Jha R Br J Hosp Med (Lond); 2021 Mar; 82(3):1-9. PubMed ID: 33792391 [TBL] [Abstract][Full Text] [Related]
10. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627 [TBL] [Abstract][Full Text] [Related]
12. Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve. Gibson RL; Sletten ZJ; Sarkisian SA; Sjulin TJ Med J (Ft Sam Houst Tex); 2021; (PB 8-21-01/02/03):28-33. PubMed ID: 33666909 [TBL] [Abstract][Full Text] [Related]
13. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Malsy J; Veletzky L; Heide J; Hennigs A; Gil-Ibanez I; Stein A; Lütgehetmann M; Rosien U; Jasper D; Peine S; Hiller J; Haag F; Schmiedel S; Huber S; Jordan S; Addo MM; Schulze Zur Wiesch J Clin Infect Dis; 2021 Dec; 73(11):e4020-e4024. PubMed ID: 33103195 [TBL] [Abstract][Full Text] [Related]
14. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study. Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC; Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060 [TBL] [Abstract][Full Text] [Related]
15. Emerging treatment strategies for COVID-19 infection. Gavriatopoulou M; Ntanasis-Stathopoulos I; Korompoki E; Fotiou D; Migkou M; Tzanninis IG; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA Clin Exp Med; 2021 May; 21(2):167-179. PubMed ID: 33128197 [TBL] [Abstract][Full Text] [Related]
16. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery. Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605 [TBL] [Abstract][Full Text] [Related]
17. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Martinez MA Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082 [TBL] [Abstract][Full Text] [Related]
18. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of Han YJ; Lee KH; Yoon S; Nam SW; Ryu S; Seong D; Kim JS; Lee JY; Yang JW; Lee J; Koyanagi A; Hong SH; Dragioti E; Radua J; Smith L; Oh H; Ghayda RA; Kronbichler A; Effenberger M; Kresse D; Denicolò S; Kang W; Jacob L; Shin H; Shin JI Theranostics; 2021; 11(3):1207-1231. PubMed ID: 33391531 [No Abstract] [Full Text] [Related]
19. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. Daou F; Abou-Sleymane G; Badro DA; Khanafer N; Tobaiqy M; Al Faraj A Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33499310 [TBL] [Abstract][Full Text] [Related]